CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
PEG-interferon alfa-2bbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00045279
NCT00045279Phase 2Completed
CompareCT.gov

Phase II Trial of PEG-Intron in Patients With Advanced Renal Cell Carcinoma

Memorial Sloan Kettering Cancer Center·interventional·Posted Jan 27, 2003·Updated Jun 5, 2013

In Brief

A Phase 2 clinical trial evaluating PEG-interferon alfa-2b for Kidney Cancer. Completed, across 1 site.

Detailed Summary

RATIONALE: PEG-interferon alfa-2b may stop the growth of kidney cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of PEG-interferon alfa-2b in treating patients who have metastatic kidney cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2003
Enrollment StartApr 1, 2002
Primary CompletionSep 1, 2005
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 23.4 years ago

Interventions

PEG-interferon alfa-2bbiological